202 related articles for article (PubMed ID: 17287337)
1. Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
Williams NS; Burgett AW; Atkins AS; Wang X; Harran PG; McKnight SL
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2074-9. PubMed ID: 17287337
[TBL] [Abstract][Full Text] [Related]
2. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
[TBL] [Abstract][Full Text] [Related]
3. Diazonamide toxins reveal an unexpected function for ornithine delta-amino transferase in mitotic cell division.
Wang G; Shang L; Burgett AW; Harran PG; Wang X
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2068-73. PubMed ID: 17287350
[TBL] [Abstract][Full Text] [Related]
4. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.
Wieczorek M; Tcherkezian J; Bernier C; Prota AE; Chaaban S; Rolland Y; Godbout C; Hancock MA; Arezzo JC; Ocal O; Rocha C; Olieric N; Hall A; Ding H; Bramoullé A; Annis MG; Zogopoulos G; Harran PG; Wilkie TM; Brekken RA; Siegel PM; Steinmetz MO; Shore GC; Brouhard GJ; Roulston A
Sci Transl Med; 2016 Nov; 8(365):365ra159. PubMed ID: 27856798
[TBL] [Abstract][Full Text] [Related]
5. Chemistry and biology of diazonamide A: second total synthesis and biological investigations.
Nicolaou KC; Hao J; Reddy MV; Rao PB; Rassias G; Snyder SA; Huang X; Chen DY; Brenzovich WE; Giuseppone N; O'Brate A; Giannakakou P
J Am Chem Soc; 2004 Oct; 126(40):12897-906. PubMed ID: 15469287
[TBL] [Abstract][Full Text] [Related]
6. Interaction of diazonamide A with tubulin.
Bai R; Cruz-Monserrate Z; Fenical W; Pettit GR; Hamel E
Arch Biochem Biophys; 2020 Feb; 680():108217. PubMed ID: 31830440
[TBL] [Abstract][Full Text] [Related]
7. Towards modern anticancer agents that interact with tubulin.
La Regina G; Coluccia A; Naccarato V; Silvestri R
Eur J Pharm Sci; 2019 Apr; 131():58-68. PubMed ID: 30690185
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action and resistance to tubulin-binding agents.
Dumontet C
Expert Opin Investig Drugs; 2000 Apr; 9(4):779-88. PubMed ID: 11060709
[TBL] [Abstract][Full Text] [Related]
9. Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo.
Trendowski M; Wong V; Wellington K; Hatfield S; Fondy TP
In Vivo; 2014; 28(6):1021-31. PubMed ID: 25398795
[TBL] [Abstract][Full Text] [Related]
10. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system.
Canta A; Chiorazzi A; Cavaletti G
Curr Med Chem; 2009; 16(11):1315-24. PubMed ID: 19355888
[TBL] [Abstract][Full Text] [Related]
11. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
Dumontet C; Sikic BI
J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
[TBL] [Abstract][Full Text] [Related]
13. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
[TBL] [Abstract][Full Text] [Related]
14. Natural products as antimitotic agents.
Dall'Acqua S
Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
[TBL] [Abstract][Full Text] [Related]
15. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
16. Microtubulin binding sites as target for developing anticancer agents.
Islam MN; Iskander MN
Mini Rev Med Chem; 2004 Dec; 4(10):1077-104. PubMed ID: 15579115
[TBL] [Abstract][Full Text] [Related]
17. Novel aspects of natural and modified vinca alkaloids.
Duflos A; Kruczynski A; Barret JM
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
[TBL] [Abstract][Full Text] [Related]
18. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
19. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
20. Advances in vinca-alkaloids: Navelbine.
Marty M; Extra JM; Espie M; Leandri S; Besenval M; Krikorian A
Nouv Rev Fr Hematol (1978); 1989; 31(2):77-84. PubMed ID: 2671933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
